Targeting both EGFR and VEGF-A via a bispecific antibody binding potentially enhances anti-tumor activity not only by inhibiting EGFR signaling in OC, but also by blocking angiogenic activity in endothelial cells that support tumor growth and progression. The gene discussed is EGFR; the disease is neoplasm.